France has begun the first human trial of artificial heart, which aims at overcoming shortages of organs available for transplant.
The implant operation, which took place on Wednesday at the Georges Pompidou Hospital in Paris, "went satisfactorily," it said in a statement.
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to avoid heart attack are listed.
Advertisement
The patient, whom it did not name, is in intensive care, "is conscious and speaking to relatives," Carmat said, adding that it was too early to draw wider conclusions about the operation.
Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.
Tens of thousands of people with hearts damaged by disease or a heart attack die each year because of a lack of a donor.
![Quiz on Heart Attack]( "Quiz on Heart Attack")
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.
The Carmat product aims at providing a longer-term solution to bridge the wait and enable hospitalised patients to return home and maybe even resume work.
A self-contained unit implanted in the patient's chest, it uses soft "biomaterials" and an array of sensors, rather than a pump, to mimic the contractions of the heart.
The goal is to lessen the risk of blood clots and rejection by the immune system.
Power comes from an external source or wearable lithium batteries.
The company was authorised in September by French health watchdogs to carry out four trials in three hospitals after tests on animals.
The 900-gramme (31-ounce) device is the outcome of a years-long collaboration between cardiac surgeon Alain Carpentier and the European aerospace giant EADS.
Nearly 100,000 people in Europe and the United States are in need of a heart transplant, according to Carmat.
The price of the heart is estimated at between 140,000 and 180,000 euros ($190,000 and $244,000).
Phase I of the trial, on the small group of volunteers in terminal condition, will assess survival one month after the operation, or earlier if the patient receives a natural heart.
If all goes well, a second phase, conducted among a group of about 20 patients, will look at efficacy -- quality of life, comfort and side effects -- as well as safety.
A US rival to Carmat, an artificial heart called AbioCor made the biotech firm Abiomed, is authorised in the United States for patients with end-stage heart-failure or life expectancy of less than 30 days, who are not eligible for a natural heart plant and have no other viable treatment options.
Source: AFP
Tens of thousands of people with hearts damaged by disease or a heart attack die each year because of a lack of a donor.
Quiz on Heart Attack
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.
Advertisement
The Carmat product aims at providing a longer-term solution to bridge the wait and enable hospitalised patients to return home and maybe even resume work.
A self-contained unit implanted in the patient's chest, it uses soft "biomaterials" and an array of sensors, rather than a pump, to mimic the contractions of the heart.
The goal is to lessen the risk of blood clots and rejection by the immune system.
Power comes from an external source or wearable lithium batteries.
The company was authorised in September by French health watchdogs to carry out four trials in three hospitals after tests on animals.
The 900-gramme (31-ounce) device is the outcome of a years-long collaboration between cardiac surgeon Alain Carpentier and the European aerospace giant EADS.
Nearly 100,000 people in Europe and the United States are in need of a heart transplant, according to Carmat.
The price of the heart is estimated at between 140,000 and 180,000 euros ($190,000 and $244,000).
Phase I of the trial, on the small group of volunteers in terminal condition, will assess survival one month after the operation, or earlier if the patient receives a natural heart.
If all goes well, a second phase, conducted among a group of about 20 patients, will look at efficacy -- quality of life, comfort and side effects -- as well as safety.
A US rival to Carmat, an artificial heart called AbioCor made the biotech firm Abiomed, is authorised in the United States for patients with end-stage heart-failure or life expectancy of less than 30 days, who are not eligible for a natural heart plant and have no other viable treatment options.
Source: AFP
Henry Ford Hospital Pioneers New Route to the Heart to Implant an Artificial Heart Valve
At Henry Ford Hospital doctors have created a new route to the heart to implant an artificial heart valve by temporarily connecting major blood vessels that do not normally intersect.
Advertisement
 Artificial Heart Tissue That can Mimic Functions of a Real Heart Tissue DevelopedResearchers at the Brigham and Women's Hospital (BWH) revealed that they have managed to create an artificial heart tissue that can mimic the functions of the natural heart tissue. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Light therapy enhances sleep and psycho-behavioral symptoms in Alzheimer's patients with minimal side effects.
Electrical stimulation improves Alzheimer's patients' cognitive function and correlates with restored cortical plasticity.
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.